269 related articles for article (PubMed ID: 36600263)
1. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease.
Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim D; Kim YJ; Yoon JH; Han K; Cho EJ
BMC Med; 2023 Jan; 21(1):4. PubMed ID: 36600263
[TBL] [Abstract][Full Text] [Related]
2. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study.
Park MK; Hur MH; Moon HS; Shin H; Chung SW; Won S; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Liver Int; 2024 Mar; 44(3):799-810. PubMed ID: 38230848
[TBL] [Abstract][Full Text] [Related]
3. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals.
Zhang P; Zeng Y; Yang S; Ye C; Wang M; Peng T; Li L; Dong X
Sci Rep; 2024 May; 14(1):11320. PubMed ID: 38760435
[TBL] [Abstract][Full Text] [Related]
4. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
6. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
[TBL] [Abstract][Full Text] [Related]
7. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
8. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
Lee H; Lim TS; Kim SU; Kim HC
Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
[TBL] [Abstract][Full Text] [Related]
9. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
10. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
11. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
[TBL] [Abstract][Full Text] [Related]
12. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
[TBL] [Abstract][Full Text] [Related]
13. Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis.
Fukunaga S; Nakano D; Tsutsumi T; Kawaguchi T; Eslam M; Yoshinaga S; Abe H; Nouno R; Joh S; Mitsuyama K; George J; Torimura T
Hepatol Res; 2022 Aug; 52(8):699-711. PubMed ID: 35585481
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
[TBL] [Abstract][Full Text] [Related]
16. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
[TBL] [Abstract][Full Text] [Related]
17. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
18. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.
Xie ZQ; Li HX; Wang BK; Yang ZM; Zhang ZY; Tan WL; Li WX; Wang QB; Yang L; Zhuang HK; Tang CW; Shang CZ; Chen YJ
Eur J Intern Med; 2023 Apr; 110():62-70. PubMed ID: 36754655
[TBL] [Abstract][Full Text] [Related]
19. The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals.
Chan KE; Ng CH; Fu CE; Quek J; Kong G; Goh YJ; Zeng RW; Tseng M; Aggarwal M; Nah B; Chee D; Wong ZY; Zhang S; Wang JW; Chew NWS; Dan YY; Siddiqui MS; Noureddin M; Sanyal AJ; Muthiah M
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2560-2569.e15. PubMed ID: 36202348
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]